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TLR ligands (TLR-Ls) represent a class of novel vaccine adjuvants. However, their immunologic effects in
humans remain poorly defined in vivo. Using a humanized mouse model with a functional human
immune system, we investigated how different TLR-Ls stimulated human innate immune response
in vivo and their applications as vaccine adjuvants for enhancing human cellular immune response.
We found that splenocytes from humanized mice showed identical responses to various TLR-Ls as human
PBMCs in vitro. To our surprise, various TLR-Ls stimulated human cytokines and chemokines differently
in vivo compared to that in vitro. For example, CpG-A was most efficient to induce IFN-a production
in vitro. In contrast, CpG-B, R848 and Poly I:C stimulated much more IFN-a than CpG-A in vivo.
Importantly, the human innate immune response to specific TLR-Ls in humanized mice was different
from that reported in C57BL/6 mice, but similar to that reported in nonhuman primates. Furthermore,
we found that different TLR-Ls distinctively activated and mobilized human plasmacytoid dendritic cells
(pDCs), myeloid DCs (mDCs) and monocytes in different organs. Finally, we showed that, as adjuvants,
CpG-B, R848 and Poly I:C can all enhance antigen specific CD4+ T cell response, while only R848 and
Poly I:C induced CD8+ cytotoxic T cells response to a CD40-targeting HIV vaccine in humanized mice, cor-
related with their ability to activate human mDCs but not pDCs. We conclude that humanized mice serve
as a highly relevant model to evaluate and rank the human immunologic effects of novel adjuvants
in vivo prior to testing in humans.1. Introduction
The most effective vaccines are live attenuated vaccines such as
the yellow fever vaccine YF-17D [1] and smallpox vaccine [2,3],
providing long-lasting protective immunity with a single adminis-
tration. It has become clear that, by activating pathogen-encoded
pattern recognition receptors (PRRs) on immune effector cells,
these vaccines can efficiently activate the innate immune system
to induce efficient antigen-specific humoral and cytotoxic T
lymphocytes (CTL) responses [4,5]. Conversely, recombinant
antigen-based vaccines are often poorly immunogenic and needco-administered adjuvants to enhance the protective immunity
especially the CTL response [5].
Toll like receptor (TLRs) represent an important type of PRRs
that can sense the microbial components named pathogen-
associated molecular patterns (PAMPs) [6,7]. TLRs are expressed
by various cells, especially by the innate immune cells such as
monocytes, myeloid dendritic cells (mDCs) and plasmacytoid
dendritic cells (pDCs) [6,7]. Stimulation of these innate immune
cells with natural or synthetic TLR ligands (TLR-Ls) results in
up-regulation of co-stimulatory molecules, enhanced expression
of MHC class II molecules, and production of inflammatory cytoki-
nes [8,9]. Thus, natural ligands or synthetic agonists for TLRs are
being developed as potential new vaccine adjuvants [10,11]. For
example, Monophosphoryl Lipid A (MPLA), a derivative
lipopolysaccharide which acts through TLR4, has been approved
for clinic application as a component of AS04 adjuvant in Cervarix
vaccine against cervical cancer and the vaccine against hepatitis B
virus [12].
Although the adjuvant effects of TLR-Ls are promising, their
immunological effects in vivo in humans are still poorly under-
stood. Mouse models serve as the most widely used tools for mech-
anistic study and preclinical evaluation of TLR-Ls adjuvants.
However, fundamental differences exist between human and
mouse since the two species diverged between 65 and 75 million
years ago, and knowledge gained from mouse studies does not
always apply to humans [13,14]. For example, preclinical toxicol-
ogy study in mice did not provide any indication that fialuridine
would be hepatotoxic to human beings [15], but 5 of 15 clinical
trial participants died and the other two required a liver transplant
after receiving a nucleoside analogue fialuridine treatment due to
acute liver failure. The species-specific expression of a mitochon-
dria nucleoside transporter in human but not in mouse is probably
responsible for the human-specific liver toxicity caused by fialuri-
dine [16]. Recently, it is reported that fialuridine induced acute
liver damage in human-mouse liver chimeric TK-NOG mice [17].
The immune system of human also has diverse differences from
mouse [13]. One obvious difference is that bronchus-associated
lymphoid tissue is only developed in mice but not in healthy
humans. This has possibly evolved because mice live so much clo-
ser to the ground where they experience a higher dose of patho-
gens [13,18]. It has also been reported that the distribution of
several TLRs in innate immune cells is quite different between
human and mouse [13]. TLR9 in mouse is widely expressed on
pDC, mDC, B cells and also expressed in monocyte/macrophage lin-
eage cells [19,20], whereas in humans, it is preferentially expressed
on pDCs and B cells [21,22]. TLR8, which is expressed on mDC and
macrophage, can respond to ssRNA stimulation in human but this
is not functional in mice [23]. Moreover, TLR10, whose ligands are
as yet unknown, is widely expressed in humans but not in mice
[24]. The discrepancies in TLRs distribution between mouse and
human immune cells may limit the translation of findings into
human clinical applications, when based on mouse work.
Another commonly used tool for evaluating the adjuvant effects
of the TLR-Ls is the human peripheral blood mononuclear cells
(PBMCs) in vitro culture system. However, this cell culture system
is not useful to study non-circulating cells that also respond to TLR-
Ls stimulation in vivo [25]. The other fundamental limitation of the
human PBMCs in vitro culture system is that it cannot authenti-
cally reflect the cell-cell interaction environment in vivo. The
dynamics and accessibility of the drugs to the cells should also
be different in vivo compared to that in vitro. It is also difficult
to evaluate vaccine adjuvant activity in inducing human T and B
cell responses in vitro.
Mice reconstituted with a functional human immune system
provide a valuable platform to study the development and func-
tions of human immune cells, and more importantly, to investigate
human immune response to pathogens, vaccines and other stimu-
lations in vivo [14]. We and others have shown that injection of
human CD34+ hematopoietic stem cells into the immunodefecient
BALB/c Rag2/cc/ mice or NOD-scid cc/ (NSG) mice as well as
NOD-Rag2/ cc/ (NRG) mice can reconstitute all major human
myeloid and lymphoid subsets, including monocytes, mDCs, pDCs,
T cells and B cells [26–31]. In this study, we used the humanized
NRG mice as an in vivo model to explore how the human immune
system responds to different PAMPs, specifically, how various
TLR-Ls differentially stimulate human innate immune response
and regulate adaptive CD4+ helper T cell and importantly cytotoxic
T lymphocyte (CTL) response to CD40-targeting HIV candidate ther-
apeutic vaccine in vivo. We demonstrate that human leukocytes
developed in humanized mice respond similarly to TLR-Ls stimula-
tion of human PBMCs in vitro. When tested in vivo, however,TLR-Ls induce a significantly different profile of human cytokines
and chemokines compared to that induced in vitro. We show that,
in humanized mice, various TLR-Ls differentially activate distinct
human immune cells in different lymphoid organs. Importantly,
humanized mice respond to TLR-Ls stimulation differently from
C57BL/6 mice [25] but similarly to that observed in nonhuman pri-
mates [32]. Finally, we show that, consistent with their different
abilities to activate mDCs, Poly I:C and R848 (but not CpG-B) were
able to enhance antigen-specific CTL responses to a CD40-targeting
HIV candidate vaccine in humanized mice. Our study indicates that
various TLR-Ls differentially activate human innate immune cells
to enhance antigen-specific cellular immune responses in human-
ized mice. The humanized mouse model thus provides a unique
platform to evaluate the immunologic effects of novel adjuvants
in vivo, prior to human testing.2. Materials and methods
2.1. Ethics statement
The report followed NIH research ethics guidelines. For the con-
struction of humanized mouse, human fetal liver was obtained
from elective or medically indicated termination of pregnancy
through a non-profit intermediary working with outpatient clinics
(Advanced Bioscience Resources, Alameda, CA). The use of the tis-
sue in the research had no influence on the decision regarding ter-
mination of the pregnancy. Informed consent of the maternal
donor is obtained in all cases, under regulation governing the
clinic. We were provided with no information regarding the iden-
tity of the patients, nor is this information traceable. The project
was reviewed by the University’s Office of Human Research Ethics,
which has determined that this submission does not constitute
human subjects research as defined under federal regulations [45
CFR 46.102 (d or f) and 21 CFR 56.102(c)(e)(l)] and does not require
IRB approval. The University of North Carolina at Chapel Hill Insti-
tutional Animal Care and Use Committee (IACUC) has reviewed
and approved this research. All animal experiments were con-
ducted following NIH guidelines for housing and care of laboratory
animals and in accordance with The University of North Carolina at
Chapel Hill with protocols approved by the institution’s Institu-
tional Animal Care and Use Committee (IACUC ID: 14-100).
2.2. Construction of humanized mice
We constructed humanized NRG (NOD-Rag2/ cc/) mice by
reconstitution with human fetal liver (17 to 22 weeks of gesta-
tional age) derived CD34+ hematopoietic progenitor cells
(Advanced Bioscience Resources, Alameda, CA) similarly as previ-
ously reported [30]. Humanized BLT mice were generated accord-
ing to a previous report [33]. Briefly, 6 to 8 weeks old NRG mice
were sub-lethally irradiated and anesthetized the same day, and
1-mm3 fragments of human fetal thymus were implanted under
the recipient kidney capsule. CD34+ hematopoietic progenitor cells
purified from fetal liver of same donor were injected retro-orbital
within 3 h. Human immune cell engraftment was detected by flow
cytometry 12 weeks after transplantation. All animal studies were
approved by the University of North Carolina Institutional Animal
Care and Use Committee (IACUC).
2.3. TLR-L treatment in vitro and in vivo
CpG-A (ODN 2216), CpG-B (ODN 2006), CpG-C (ODN 2395),
R848, MPLA and Poly I:C used in this study were all purchased
from InvivoGen. 1  106 total human PBMCs or splenocytes of
humanized mice containing 1  106 human CD45+ cells were used
for in vitro stimulation. Cells were stimulated with 5 mg/ml of CpG-
A, CpG-B, CpG-C, R848, Poly I:C and 2 mg/ml of MPLA for 24 h and
supernatants were collected for cytokine/chemokine detections.
For in vivo treatment, humanized mice were treated with 50 mg/
mouse of CpG-A, CpG-B, CpG-C, R848, Poly I:C or 20 mg/mouse of
MPLA through i.p. injection.2.4. Detection of cytokines/chemokines
Human IFN-a was detected by enzyme-linked immunosorbent
assay using the human IFN-a pan ELISA kits purchased from Mab-
tech. A high sensitivity immunology multiplex assay (Luminex)
(Millipore, Billerica, Massachusetts, USA) was used to measure
human IL-12, IL-6, IFN-c, TNF-a, IL-1b, IP-10, MCP-1, IL-8, IL-4
and IL-10 in plasma of humanized mice or cell culture supernatant
according to the manufacturer’s instructions.2.5. Flow cytometry
For surface staining, single cell suspensions prepared from
peripheral blood, spleen, or bone marrow of humanized mice were
stained with surface markers and analyzed on a CyAn ADP (Dako).
For intracellular cytokine staining, cells were first stained with sur-
face markers, and then permeabilized with cytofix/cytoperm buffer
(BD Bioscience), followed by intracellular staining. FITC-conjugated
anti-human CD40, CD56, PE-conjugated anti-human CD303, PE/
Cy5-conjugated anti-human CD4, CD86, PE/Cy7-conjugated anti-
human CD3, HLA-DR, PB-conjugated anti-human CD4, CD14, IL-2,
APC-conjugated anti-human CD123, CD11c, TNF-a and APC/Cy7-
conjugated anti-human CD45 were purchased from Biolegend.
Pacific orange-conjugated anti-mouse CD45, PE/Texas red-
conjugated anti-human CD3, CD19, CD8 and LIVE/DEAD Fixable
Aqua (LD7) Dead Cell Stain Kit were purchased from Invitrogen.
Data were analyzed using Summit4.3 software (Dako).2.6. Vaccination and antigen-specific T cell response detection
Recombinant anti-human CD40 antibody fused to 5 HIV peptide
regions (aCD40-HIV5pep) was produced as previously reported
[34], except that the HIV peptide and flexible linker sequences
were reconfigured and the CD40 binding variable regions were
changed to a human framework. These changes had no impact
on CD40 binding or efficacy in expansion of antigen-specific T cells
in vitro. Humanized BLT mice were intramuscularly (half dose) and
intraperitoneally (half dose) injected with 10 mg aCD40-HIV5pep
alone or with 50 mg of each TLR-L two times at 3 week intervals.
Splenocytes from vaccinated humanized mice were collected
10 days after the second vaccination and stimulated ex vivo with
5 specific HIV long peptides [34] plus a-CD28 for 12 h. Brefeldin
A was added during the last 4 h of stimulation and IL-2, TNF-a
expression by CD4+ and CD8+ T cells were detected by intra-
cellular staining. IFN-c production was detected by ELISPOT after
24 h of stimulation with 5 specific HIV long peptides plus a-CD28.2.7. Statistics
Statistical analysis was performed using the two-tailed,
unpaired Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001; ns,
non-significant) using GraphPad Prism 5 software (GraphPad Soft-
ware, La Jolla, CA).3. Results
3.1. Human PBMCs and human leukocytes developed in humanized
NRG mice respond similarly to TLR-L stimulation in vitro
We reconstituted newborn NRG mice with human fetal liver
derived CD34+ hematopoietic stem/progenitor cells and detected
the development of human leukocytes 3 months after human cell
transplant. All major human CD45+ leukocyte subsets including T
cells (CD3+), B cells (CD19+), NK cells (CD3CD56+), monocytes/
macrophages (CD3CD19HLADR+CD14+), mDCs (CD3CD19
HLADR+CD14CD11c+) and pDCs (CD3CD19HLADR+CD303+)
were developed in humanized NRG mice (Supplemental Fig. 1).
In order to test whether the innate immune cells reconstituted in
humanized NRG mice were functional, we stimulated splenocytes
isolated from humanized mice in vitro with the TLR9-Ligands
CpG-A, CpG-B, CpG-C [35,36], the TLR7/8-L R848 [37], the TLR4-L
MPLA [38] and the TLR3-L Poly I:C [25]. Human cytokines and
chemokines were measured as functional readout for activation
of immune cells. In parallel, results were also obtained from
human PBMCs stimulated with the same individual TLR-Ls
in vitro. As shown in Fig. 1A, various TLR-Ls differentially stimu-
lated the production of cytokines including IFN-a, IL-6, TNF-a
and IL-12 from splenocytes of humanized mouse. Importantly,
the cytokine induction profile from splenocytes of humanized mice
was comparable to that induced from human PBMCs in vitro
(Fig. 1B). These results indicate that functional human innate
immune cells are developed in humanized NRG mice 3 months
after transplantation with human hematopoietic stem/progenitor
cells.3.2. TLR-Ls stimulate different human cytokine production profiles
in vivo compared to that in human PBMCs in vitro
To assess the early effects of TLR-Ls on systemic human
immune responses in vivo, we treated humanized NRG mice with
various TLR-Ls. We monitored the dynamics of each human cyto-
kine and chemokine level at different time points after TLR-Ls
treatment in vivo and the peak values were shown (Fig. 2 and Sup-
plemental Fig. 2A). Distinct TLR-Ls stimulated human innate
immune response differentially as indicated by inducing different
amounts of human IFN-a, IL-12, IL-6, TNF-a, IP-10, MCP-1 and
IL-8 in the serum after treatment (Fig. 2 and Supplemental
Fig. 2A). Among the TLR-Ls tested, CpG-B, R848 and Poly I:C were
more potent than other TLR-Ls to stimulate production of IFN-a
and other proinflammatory cytokines and chemokines (Fig. 2 and
Supplemental Fig. 2A).
To our surprise, we found that the array of human cytokines and
chemokines stimulated by specific TLR-Ls in vivo was significantly
different from that induced from human PBMCs or splenocytes of
humanized mice in vitro (Figs. 1 and 2). As shown in Fig. 1B,
CpG-A was most efficient in stimulating IFN-a production
in vitro (16,218 ± 5861 pg/ml). However, it only induced a minimal
amount of IFN-a (25 ± 9 pg/ml) in vivo (Fig. 2A). In contrast, R848
induced a low level of IFN-a (162 ± 84 pg/ml) in vitro (Fig. 1B),
while it robustly induced IFN-a (10801 ± 4275 pg/ml) in vivo
(Fig. 2A). Also in contrast to CpG-A, both CpG-B and Poly I:C
induced very low levels of IFN-a from human PBMCs in vitro
(Fig. 1B). However, CpG-B and Poly I:C both stimulated much more
IFN-a production in humanized mice (1039 ± 276 pg/ml and
522 ± 265 pg/ml respectively) than CpG-A (25 ± 9 pg/ml)
(Fig. 2A). TLR4-L MPLA stimulated no significant production of
IFN-a both in vitro and in vivo (Figs. 1B and 2A).
The induction profile of human IL-12 production was also dif-
ferent between in vivo and in vitro in response to TLR-Ls. Poly I:
Fig. 1. TLR-Ls induce similar human cytokine production profiles from human PBMCs and splenocytes of humanized mice. Freshly isolated splenocytes from humanized mice
or human PBMCs were stimulated with indicated TLR-Ls in vitro. Cytokine levels in culture supernatant were detected at 24 h after stimulation. Graph represents mean
cytokine levels from splenocytes of humanized mice with 3 different human donor tissues (A) or PBMCs from 5 different donors (B).
Fig. 2. Various TLR-Ls differently stimulate human cytokine production in vivo. Humanized mice were injected intraperitoneally with indicated TLR-Ls or PBS. IFN-a, IL-12
levels in plasma were detected at 9 h after treatment (A and B). IL-6 level was detected at 4 h after treatment (C). TNF-a level was detected at 1 h after treatment (D). Graphs
represent the mean of 3–4 mice each group. Three independent experiments were performed with similar results.C and R848 stimulated similar level of IL-12 while CpG-B did not
induce significant level of IL-12 in vitro (Fig. 1B). We found that
in vivo Poly I:C induced around 20-fold higher IL-12 production
than R848 or CpG-B (Fig.2B). MPLA stimulated a low level of IL-
12 in vitro and in vivo (Figs. 1B and 2B).
The proinflammatory cytokines IL-6, TNF-a and chemokines IP-
10, MCP-1 and IL-8 induced by distinct TLR-Ls also varied between
in vivo and in vitro systems (Figs. 1, 2 and Supplemental Fig. 2). The
data above indicate that different TLR-Ls distinctively stimulate
cytokine and chemokine production in humanized NRG mice
in vivo, but these profiles are different to those observed from
human PBMCs, as well as splenocytes from the humanized mouse,
in vitro. These data suggest that the immunological effect of TLR-Ls
in vitro does not predict their effect in vivo.
3.3. Kinetics of human cytokine production in vivo after TLR-Ls
treatment
The results above showed that CpG-B, R848 and Poly I:C are
more efficient than other TLR-Ls in stimulating production of
human proinflammatory cytokines and chemokines in vivo in
humanized mice. We further characterized the induction kinetics
of human cytokines and chemokines by these three TLR-Ls in
humanized mice. IFN-a was robustly induced by R848 at 1 h after
injection, and reached peak level at 4 h (Fig. 3A). After 48 h, the
IFN-a level was only slightly reduced (Fig. 3A). In contrast, CpG-B
and poly I:C stimulated slower and lower IFN-a expression and
the IFN-a level became undetectable after 48 h (Fig. 3A). However,
IL-12 induced by Poly I:C was higher and persisted longer in theplasma (Fig. 3B). Both Poly I:C and R848 induced higher level of
IL-6 than CpG-B (Fig. 3C). Induction of other cytokines such as
TNF-a, IFN-c and IL-1b; and chemokines such as IP-10, MCP-1,
and IL-8 also showed different kinetics after CpG-B, R848 or Poly
I:C treatment (Fig. 3 and Supplemental Fig. 3). All the TLR-Ls tested
induced only very low levels of anti-inflammatory cytokine IL-10
and they did not induce detectable Th2 cytokine IL-4 (Supplemen-
tal Fig. 3).
3.4. Humanized mice respond to TLR-Ls stimulation differently from
C57BL/6 mice but similarly to that reported in nonhuman primates
Mouse models have been widely used for mechanistic study
and preclinical evaluation of TLR-Ls adjuvants. Since the expres-
sion of several TLRs in immune cells is quite different between
human and mice [13], we investigated whether TLR-Ls differen-
tially activate human and mouse immune response in vivo. It
was reported that CpG-B induced a high level of mouse cytokines
IL-6, TNF-a, IL-12 and IFN-c in C57BL/6 mice [25]. In marked con-
trast, our result showed that, in comparison with Poly I:C and
R848, CpG-B only induced very low levels of human IL-6, TNF-a,
IL-12 and IFN-c in humanized mice (Fig. 3 and Supplemental
Fig. 3). Study in nonhuman primates such as Rhesus macaques,
which has closer genetic relationship to human, also indicated that
CpG-B induced low levels of IL-6, TNF-a, and IFN-c [32] when
administered in vivo. Importantly, CpG-B therapy in mildly asth-
matic human patients also did not stimulate TNF-a production
[39]. Our in vivo data further explain the fact that CpG-B elicits
TNF-a–dependent toxicity in rodents but not in humans [39].
Fig. 3. Kinetics of human cytokine production after TLR-Ls treatment in humanized mice. Humanized mice were injected intraperitoneally with CpG-B, R848, Poly I:C or PBS.
Cytokines and chemokines in plasma were measured at the indicated time points after TLR-Ls injection. Graphs represent the mean of 3–4 mice each group. Three
independent experiments were performed with similar results.These results indicate that the immunological effect of CpG-B in
humanized mice, but not in mice, is more relevant to the situation
in humans.
Poly I:C treatment in C57BL/6 mice leads to higher amounts of
mouse IFN-a production than R848 and CpG-B [25]. In contrast, we
found here that R848 was the superior human IFN-a inducer in
humanized mice (Fig.3A). Similar to the result observed in Rhesus
macaques [32], R-848 treatment induced rapid and abundant pro-
duction of pro-inflammatory cytokines in humanized mice (Fig. 3
and Supplemental Fig. 3). Taken together, these results indicate
that mouse and human immune system respond differentially to
in vivo administered TLR-Ls stimulation. Thus, knowledge about
the immunological effect of TLR-Ls in mouse is not always
applicable to humans. The similarity of immune responses to
specific TLR-Ls between humanized mice and nonhuman primates
support the use of humanized mouse model to study the human
immunological effects of TLR-Ls, in vivo.
In summary, different TLR-Ls showed variable abilities to stim-
ulate production of human cytokines and chemokines in vivo in
humanized mice. Importantly, the human cytokine and chemokineproduction profile induced by TLR-Ls in vivo was quite different
compared to that induced in vitro from human PBMCs or spleno-
cytes of humanized mouse. The data indicate that the immunologi-
cal effect of TLR-Ls on human PBMC in vitro cannot simply apply to
that in vivo. Results also showed that humanized mice responded
to TLR-Ls stimulation differently from C57BL/6 mice, but similarly
to that in nonhuman primate (Table 1). Thus, humanized mice pro-
vide a unique platform to study the human immunological effect of
TLR-Ls and novel adjuvants in vivo.
3.5. Different TLR-Ls distinctively activate and mobilize human
monocytes/ macrophages, mDCs and pDCs in peripheral blood, spleen
and lymph nodes
We further characterized the effects of TLR-Ls in vivo by mea-
suring the expression level of surface activation markers (CD40,
CD86, HLA-DR) on various human innate immune cells in different
organs. We found that CpG-B preferentially activated CD303+ pDCs
in the peripheral blood, spleen and mesenteric lymph nodes
(mLNs) while it had minimal effect on CD14+ monocytes/
Table 1
Cytokines induced by TLR-Ls in humanized mice in vivo resemble that in Rhesus macaque but different from that in C57BL/6 mice.
Cytokines induced Stimulation conditions
Humanized mouse in vivo Rhesus macaque in vivo (32) C57BL/6 mouse in vivo (25)
CpG-B R848 Poly I:C MPLA CpG-B R848 Poly I:C MPLA CpG-B R848 Poly I:C LPS
IFN-a ++ ++++ ++ – ++ ++++ NA – +/ ++ ++++ –
IL-12p70 + + +++ +/ NA NA NA NA – – – –
IL-6 + +++ +++ +/ + +++ NA +/ +++ +++ +++ ++
IFN-c + +++ ++ +/ + +++ NA – ++++ ++ ++ +
Summary of cytokines (IFN-a, IL-12p70, IL-6 and IFN-c) induced by different TLR-Ls in humanized mice in vivo, in Rhesus macaque (32) and C57BL/6 mice (25) in vivo. ++++,
+++, ++, + and  indicate the relative levels of cytokine. Levels of cytokines induced in humanized mice, rhesus macaques, and C57BL/6 mice shown here represent their peak
levels after treatment in vivo. NA, assays not performed in the experiments.macrophages and CD11c+ mDCs in peripheral blood and spleen
(Fig. 4A–C). However, monocytes/macrophages from the mLNs
expressed a higher level of this activation marker in the CpG-B
treated group than control mice (Fig. 4A). Poly I:C was most potent
in activating mDCs, but not pDCs, in the peripheral blood, spleen,
and mLNs (Fig. 4A–C). It significantly up-regulated the expression
of CD40, CD86 and HLA-DR on monocytes/macrophages from trea-
ted mLNs but not peripheral blood or spleen (Fig. 4A). Since mono-
cytes do not express TLR-9 and TLR-3, their activation by CpG-B
and Poly I:C in the mLN may be indirect. R848 triggered the activa-
tion of a broader spectrum of immune cells, including pDCs, mDCs
and also monocytes/macrophages from peripheral blood, spleen
and mLNs (Fig. 4A–C).
In addition, we found that frequency of monocytes and mDCs
decreased in the peripheral blood and spleen 24 h after R848 and
Poly I:C treatment. In contrast, R848 and Poly I:C treatment
increased the frequency of monocytes and dendritic cells in the
mesenteric LNs (Fig.4D). These data suggest that after R848 and
Poly I:C treatment, human monocytes and cDCs migrated to the
LNs.
In summary, the results above indicated that TLR-Ls systemi-
cally and differentially activated human immune cells, in vivo, in
different organs; with CpG-B preferentially activating pDCs, Poly
I:C being more potent in activating mDCs, while R848 activated
both mDCs and pDCs. Thus, by using the humanized mouse model
we can investigate the human immunological effects of TLR-Ls on
different immune target cells in different lymphoid organs and
evaluate or develop novel human adjuvants based on such multi-
ple parameters.
3.6. Poly I:C, R848 and CpG-B have different efficacy for enhancing
antigen-specific T cell response
Recombinant antigen-based vaccines are often poorly immuno-
genic and need adjuvants to induce efficient protective immunity,
especially the CTL response [5]. Since TLR-Ls CpG-B, R848, and Poly
I:C are better than other TLR-Ls tested here to activated human
innate immune system in vivo, we further tested their ability to
enhance antigen-specific T cell response to a CD40-targeting HIV
vaccine, which is based on a recombinant anti-human CD40 anti-
body fused via the heavy (H) chain C-terminus to a string of the
5 HIV peptides (aCD40-HIV5pep) [34]. Humanized BLT (CD34+
HSC, fetal liver, and thymus) mice were immunized with aCD40-
HIV5pep with or without individual TLR-L as adjuvant. Antigen-
specific T cell responses were evaluated one week after the boost
vaccination. As shown in Fig. 5A and B, after ex vivo stimulation
with antigen-specific peptides, CD4+ cells from vaccinated mice
with all three TLR-Ls as adjuvant, produced significantly higher
levels of intracellular IL-2 and TNF-a than non-vaccinated control
mice or vaccinated mice without adjuvant. In contrast, antigen-
specific CD8+ T cell responses were only detected in vaccinated
mice with Poly I:C and R848, but not CpG-B, as adjuvant(Fig. 5C and D). PolyI:C as adjuvant also enhanced the ability of
antigen-specific T cells to produce IFN-c after stimulation with
peptides ex vivo (Fig. 5E).3.7. The different ability of Poly I:C, R848 and CpG-B to enhance
antigen-specific CTL response correlates with their ability to activate
mDC
To induce antigen-specific CTL responses, exogenous protein
vaccines need to be processed and cross-presented with MHC class
I molecules by specific dendritic cells [10]. It is reported that,
in vitro, both mDCs and pDCs from human lymphoid organs can
cross-present soluble antigens [40,41]. Our data indicated that,
in vivo, Poly I:C and R848 but not CpG-B as adjuvant enhanced
antigen-specific CTL response to a protein based vaccine (Fig. 5).
Of these three adjuvants, Poly I:C only activated human mDCs,
R848 activated both human mDCs and pDCs, while CpG-B prefer-
entially activated human pDCs in different lymphoid organs
in vivo (Fig. 4). These results suggest that, in vivo, activation of
human mDCs but not pDCs is important for inducing antigen-
specific CTL response to protein based vaccination.
CpG-B has been reported to activate and promote the cross-
presentation ability of mouse pre-CD8a+ mDC [42] and mouse
bone marrow-derived mDCs [43]. It also induces a sustained high
level of IL-12 expression in mouse [44]. Thus, as adjuvant, CpG-B
can significantly enhance mouse CTL responses to protein or pep-
tide vaccine in mice [45,46] which is different from our data in
humanized mice here. Again, our results suggest that the adjuvant
activity of TLR-Ls in mice is distinct from that in humans.
Taken together, our data indicate that, consistent with their dif-
ferent abilities for activating human mDCs, Poly I:C and R848 but
not CpG-B have the ability to induce human CTL response to
antigen-based vaccine. Thus, humanized mice provide a unique
and highly relevant in vivo model to test human innate response,
which can define intrinsic adjuvant activity and resulting enhance-
ment of vaccine antigenicity prior to human testing.4. Discussion
TLR-Ls, which can activate the innate immune system through
specific receptors, are widely recognized as potential vaccine adju-
vants [10]. Therefore, understanding the immunological effect of
TLR-Ls, in vivo in humans, is essential for applying them in the
clinic. Mouse models have served as the most widely used tools
for mechanistic study and preclinical evaluation of TLR-Ls as adju-
vants. However, since human and mouse diverged between 65 and
75 million years ago, fundamental differences exist between the
two species, in particular in their innate immune systems [13]. In
the present study, we took advantage of the well-developed
humanized mouse model to study how distinct TLR-Ls stimulated
the human immune system and as adjuvants in vivo. We report the
Fig. 4. Distinct TLR-Ls differentially activate human monocytes, mDC, and pDCs in different lymphoid organs. Humanized mice were injected intraperitoneally with CpG-B,
R848, Poly I:C or PBS. Leukocytes from peripheral blood, spleen, and LNs were isolated for flow cytometry analysis 24 h after treatment. The MFI for CD40, CD86 and HLA-DR
on CD14+ monocytes (A), CD11 c+ mDCs (B) and CD303+ pDCs (C) in blood, spleen, and LNs was shown. (D) Relative frequencies (compared with PBS group) of monocytes (left
panel) and cDCs (right panel) in blood, spleen, and LNs 24 h after TLR-Ls treatment were summarized. Graphs represent the mean of 3–4 mice each group. Two independent
experiments were performed with similar results.following novel findings: (1) we proved that leukocytes from
spleens of humanized mice respond similarly to 6 different TLR
agonists as human PBMCs in vitro. (2) We found that TLR-Ls stim-
ulated distinct human cytokine production profiles in humanized
mice in vivo, compared with that in vitro. (3) Humanized mice
responded to TLR-Ls stimulation differently from C57BL/6 mice,
but similarly to that reported in nonhuman primates. (4) We
demonstrated that, consistent with their different abilities to acti-
vate human mDCs, Poly I:C and R848 but not CpG-B were able to
enhance antigen-specific CTL responses to a protein based vaccine
in humanized mice.We report here that TLR-Ls activated the human immune
response differently from that in mice. It is reported that CpG-B
treatment in mice induced high levels of pro-inflammatory cytoki-
nes IL-6, TNF-a, IL-12 and IFN-c, comparable to that induced by
R848 or Poly I:C [25]. However, CpG-B induced much lower levels
of human IL-6, TNF-a, IL-12 and IFN-c in humanized mice in com-
parison to R848 and Poly I:C (Fig. 3). The distinct expression pat-
terns of TLR-9 in mouse and human probably contribute to the
different immunological effect induced by CpG-B [13]. Our results
explained why CpG-B elicits TNF-a-dependent toxicity in mice but
not in humans [39]. Thus, knowledge about the immunological
Fig. 5. CpG-B, R848 and Poly I:C differentially enhance antigen-specific CD4+ and CD8+ T cell responses to vaccination. Humanized BLT mice (with both human HSC and
thymus co-transplant) were vaccinated with aCD40-HIV5pep alone or with indicated TLR-Ls twice at 3 weeks interval. Mice were euthanized 10 days after boost. Splenocytes
from vaccinated humanized mice were stimulated ex vivo with the 5 specific HIV long peptides plus a -CD28 mAb. IL-2 and TNF-a expression by CD4+ and CD8+ T cells were
detected by intracellular staining. IFN-c production was detected by ELISPOT assay. (A and B) Representative plots and summarized data show percentages of IL-2+ and TNF-
a+ CD4+ T cells. (C-D) Representative plots and summarized data show percentages of IL-2+ and TNF-a+ CD8+ T cells. Each dot represents one individual mouse with 3 mice
each group. Two independent experiments with similar results were performed. (E) IFN-c production after 5 specific HIV long peptides plus a -CD28 stimulation. Shown are
combined data from two independent experiments with 6 mice from each group.
effect of TLR-Ls in humanized mice will be critical to evaluate
human innate immune activation and adjuvant activity relevant
to humans.
We also compared our data with reported work in nonhuman
primates [32]. We found that TLR-Ls stimulated similar innate
immune response in humanized mice as in Rhesus macaque, which
has closer genetic relationship to human. Herein, we conclude that
the humanized mouse serves as a highly relevant small animal
model to test human immunological activity of TLR-Ls, in vivo.
In this study, we also demonstrated that TLR-Ls stimulated the
human innate immune response differently in vivo compared to
that in vitro. Three major classes of stimulatory CpG oligodeoxynu-
cleotides (CpG ODN) have been identified based on their structural
characteristics and activity on human pDCs and B cells [35,47].
Type I IFNs play important roles in stimulating dendritic cell mat-
uration and migration, and enhancing humoral immunity as well
as modulating effector and memory T cell response [48]. Therefore,
CpG-A, which can induce robust type I IFN response in vitro, may
have potential benefits as vaccine adjuvant. However, therapeutic
potential of CpG-A remained largely unexplored. Here we showed
that CpG-A, which can stimulate high levels of human IFN-a pro-
duction in vitro, did not induce significant levels of IFN-a in vivo
in humanized mice (Figs. 1 and 2). CpG-A can form uncontrollable
aggregation that complicates its manufacture [49,50]. Thus, one
possible reason that CpG-A behaves poorly in vivo activity could
be its highly aggregated structure, which may restrict its access
to spleen, lymph node or bone marrow [51,52]. In contrast, CpG-
B induced high levels of IFN-a in humanized mice in vivo
(Fig. 2). In addition to stimulating IFN-a production, CpG-B also
induced other cytokines and chemokines such as IL-6, IL-12, IFN-
c, and IP-10 in vivo in humanized mice. These results further sup-
port the development of CpG-B as vaccine adjuvant in clinical
trials.
In comparison to CpG-A, the TLR7/8-L R848 was poor in induc-
ing IFN-a, in vitro, both from human PBMCs and spleen cells from
humanized mice. However, it stimulated fast, robust, and durable
IFN-a production, in vivo, in humanized mice (Fig. 3A). In addition
to CpG-B and R848, we report here that Poly I:C is also a potent
human innate immune stimulator, in vivo, in humanized mice.
Poly I:C treatment induced significant levels of IFN-a, in vivo, but
not in vitro (Figs. 1–3). Most importantly, it stimulated much
higher and more durable levels of IL-12 than CpG-B and R848,
in vivo (Fig. 3B). Study has indicated that IL-12 plays an essential
role for the development of antigen-specific CD8+ T cell immune
responses to vaccination in humans with cancer [53].
It will be of interest to explore the mechanisms by which TLR-Ls
stimulate different cytokine production profiles, in vivo, compared
to that in vitro. Lots of variables such as; physiological conditions,
cell-cell interactions and dynamics, and accessibility of the drugs
to the cells, might contribute to the differences observed here.
Thus, the immunological effect of TLR-Ls, in vitro, cannot simply
predict their activity in vivo. Using the humanized mouse model,
we will further investigate how distinct TLR-Ls differentially stim-
ulate the human innate immune response in vivo.
From a vaccine development state point, induction of robust,
potent and durable CTL responses using a non-viral vector is chal-
lenging.Wehypothesize that targeting antigens throughaDC recep-
tor combinedwithDC stimulatorsmaybe required to optimize T cell
responses. We show here that Poly I:C and R848, which can signifi-
cantly stimulate human mDCs, induced antigen-specific CTL
response to a DC-targeting HIV vaccine. In contrast, CpG-B, which
activated human pDCs but not mDCs, enhanced antigen-specific
human CD4+ helper T cell but not CTL response in humanized mice
(Fig. 5). The results indicate that human pDCs activated by CpG-B
did not cross-present antigen to CD8+ T cells efficiently, although
several reports showed that in vitro pDCs can cross-present solubleantigen [40,41]. Taken together, our results suggest that activation
of human mDCs but not pDCs in vivo is important for inducing
antigen-specific CTL response to protein-based vaccines. Our data
is consistent with the result from human clinical trials, which show
that CpG-B preferentially enhances antibody responses and CD4+ T
cell responses to the NY-ESO-1 protein [54]. Although CD8+ T cell
responses are also detected in some vaccinated people at later time
points during vaccination, it is believed that the cross-presentation
of antigen is predominantly mediated by vaccine-induced antibody
[54].
The expression profile of several TLRs in mouse immune cells is
different from that in human immune cells. It may lead to different
adjuvant activity of TLR-Ls in mice and humans. For example, TLR-
9 is widely expressed in nearly all myeloid cells in mice but it pref-
erentially expressed in pDCs and B cells in humans. That explains
why CpG-B has been used as a potent adjuvant to enhance CTL
response in mice [45,46], which is different from our observation
here in humanized mice. Humanized mice thus will provide a crit-
ical model to test human adjuvant activity of TLR-Ls and other
novel adjuvants, in vivo, prior to clinical trials.
In conclusion, we demonstrate that different TLR-Ls distinc-
tively activate human innate immune responses and enhance
antigen-specific CD4+ or CD8+ T cell responses in humanized mice.
The results will greatly help the development of novel human
adjuvants in human clinical settings.Acknowledgments
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